Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors

Huang, Nana; Zhao, Chenchen; Hu, Xueyang; Zhang, Congjun; Xiong, Fenfen; Huang, Wei; Da, Liangshan; Shen, Yuanyuan; Wang, Hongyang

doi:10.21037/tcr-22-54

Cited by 6 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a PD-1 inhibitor, sintilimab is currently approved in China but not in other countries for tumor immunotherapy. Sintilimab displays few adverse reactions and significant efficacy against a variety of solid tumors [7]. However, there are limited reports about the treatment of UC with PD-1 inhibitor therapy alone or combined with other chemotherapeutic drugs.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Ma¹,

Hong-yuan²,

Fang³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have shown encouraging outcomes against Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer with mismatch repair deficient/microsatellite instability–high (dMMR/MSI-H). However, there is as yet no clarity on the safety and efficacy of immunotherapy combined with chemotherapy in LS-associated urothelial carcinoma (UC). Here, we report a patient with recurrent and metastatic LS-associated UC who achieved sustained response to programmed death protein 1 (PD-1) inhibitor combined with chemotherapy over 31 months, during which the side effects of immunotherapy could be controlled and managed. Our findings indicate that the dMMR/MSI status and PD-1 expression in UC may have potential predictive value for the response to PD-1-targeted immunotherapy. Our case supports the inclusion of such combination and/or monotherapy for UC in clinical studies and using dMMR/MSI status and PD-1 expression as potential predictive biomarkers for assessment of the therapeutic response.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Ma¹,

Hong-yuan²,

Fang³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…The time of occurrence was only 13 days after the treatment onset, which may be the first case report in clinical of sintilimab related ICIAM in China. Huang et al reported in a study that 48 patients with various advanced tumors were treated with sintilimab, and one of them developed ICIAM (G1) (13). Huan Bi et al reported a case with lung squamous cell carcinoma (SCC) that developed ICIAM within 6 days plus three cycles after receiving sintilimab treatment (21 days/cycle) (14).…”

Section: Discussionmentioning

confidence: 99%

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress

Zhu

Liu

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint inhibitor-associated adverse reactions (irAEs) are a clinical treatment issue that requires additional attention when ICIs have significant survival benefits in patients with advanced hepatocellular carcinoma (HCC). Among them, ICIs-associated myocarditis (ICIAM) is a kind of severe irAE with a high mortality rate (17%–50%). Despite its low incidence (PD1/PD-L1 related: 0.41%–0.8%), ICIAM can significantly disturb the decision making of therapeutic schemes and even the survival outcomes of patients. ICIAM induced by sintilimab has not been reported in any complete clinical studies yet and understanding the clinical characteristics involved may inform better practices for the management. Here, we reported a 78 y/o patient with advanced HCC, who experienced ICIAM induced by sintilimab within a short course from treatment onset and found that adequate baseline examination before the implementation of the therapeutic scheme, regular monitoring of myocardial enzymonram and cardiac imaging were measures for the early detection, while glucocorticoid pulse therapy is still the best choice with timely and sufficient application. Simultaneously, the combination of other immunosuppressants may lead to better results. New-predictive markers and examination methods are still required to facilitate the early detection.

show abstract

“…Because of the severe and fatal hepatotoxicity resulting from pazopanib therapy observed in RCC, monitoring hepatic function is urgently required during administration [ 167 ]. Further, combination therapy with sintilimab and chemotherapy (gemcitabine, oxaliplatin, capecitabine, irinotecan, nab-paclitaxel, tegafur, or nedaplatin) or sintilimab plus other anti-angiogenic agents (anlotinib or sorafenib) showed acceptable safety with rises in the treatment efficacy and DCR for advanced tumors like RCC [ 168 ]. It should be noted that due to the few adverse reactions and proven efficacy, sintilimab combination therapy can be applied as a potent strategy for the treatment of advanced RCC.…”

Section: Anti-pd-1 Antibody In Rcc Patientsmentioning

confidence: 99%

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

et al. 2022

View full text Add to dashboard Cite

Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 monoclonal antibodies, only a small portion of patients exhibit a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might ultimately favor cancer development in patients with clinical responses. In light of this, recent reports have signified that the addition of other therapeutic modalities to PD-1/PD-L1 blockade therapy might improve clinical responses in advanced RCC patients. Until, combination therapy with PD-1/PD-L1 blockade therapy plus cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor (ipilimumab) or various vascular endothelial growth factor receptors (VEGFRs) inhibitors axitinib, such as axitinib and cabozantinib, has been approved by the United States Food and Drug Administration (FDA) as first-line treatment for metastatic RCC. In the present review, we have focused on the therapeutic benefits of the PD-1/PD-L1 blockade therapy as a single agent or in combination with other conventional or innovative targeted therapies in RCC patients. We also offer a glimpse into the well-determined prognostic factor associated with the clinical response of RCC patients to PD-1/PD-L1 blockade therapy.

show abstract

Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors

Cited by 6 publications

References 29 publications

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

Contact Info

Product

Resources

About